Barclays Maintains Overweight on AnaptysBio, Lowers Price Target to $63

Benzinga Newsdesk www.benzinga.com Negative 81.7%

Neg 81.7% Neu 0% Pos 0%

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $79 to $63.